LGR5 and breast carcinoma: CUR was previously shown to target cancer cells or cancer stem cells by several mechanisms, including autophagy, G2/M phase arrest, and apoptosis in hepatoma cells (HepG2, SMMC-7721, and BEL-7402) [31], reducing the expression of stem cell markers (DCLK1/Lgr5/CD44) in colon cancer stem-like HCT-116 [32], and reducing microtentacles and preventing reattachment in breast cancer stem-like cells [33].